I medici

Dr. med.
Oreste Mora

Formazione

Laurea in medicina
1993

Specializzazione

Oncologia medica
2003
Medicina interna generale
1999

Ruolo

Specialista in oncologia e medicina interna generale
Medico accreditato

Affiliazioni

Ordine dei medici del Canton Ticino (OMCT)
Circolo medico del Mendrisiotto
European society for medical oncology (ESMO)
Società svizzera di oncologia medica (SSOM)
International society of geriatric oncology (SIOG)

Anno di nascita

1962

Inizio attività in clinica

2013

Contatto

Per l’ospedalizzazione di un paziente o per richiedere documentazione medica
T+ 41 91 960 87 12
oreste.mora@moncucco.ch
segretariato.medico@moncucco.ch

Contatto studio privato

Per fissare un appuntamento o contattare il medico
Via Luigi Lavizzari 8, 6850 Mendrisio
T+ 41 91 640 60 40

Lingue

Italiano
Inglese

Esperienze professionali

Caposervizio responsabile per l’ambulatorio di oncologia medica, Ospedale Beata Vergine di Mendrisio
2010 / 2012
Capoclinica responsabile per l’ambulatorio di oncologia medica, Ospedale Beata Vergine di Mendrisio
2006 / 2009
Capoclinica per il reparto di oncologia medica, Ospedale San Giovanni di Bellinzona
2003 / 2005

Altre attività

Membro del Comitato cantonale dell’Associazione Triangolo
Pratica di laboratorio

Pubblicazioni

Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, Bordoni A, Cavalli F, Ghielmini M. Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland. Tumori. 2009 May-Jun; 95(3):303-10.
Siano M, Lerch E, Negretti L, Zucca E, Rodriguez-Abreu D, Oberson M, Leoncini-Franscini L, Mora O, Sessa C, Gallino A, Ghielmini M. A Phase I-II Study To Determine the Maximum Tolerated Infusion-Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function. Clin Cancer Res 2008 Dec 1;14(23):7935-9.
Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R;Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clin Cancer Res. Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008 Aug 1;26(22):3702-8.
Soldini D, Mora O, Siano M, Frattini M, Cavalli F, Zucca E, Mazzuchelli L. Efficacy of Alemtuzumab and Gemcitabine in a Patient with Enteropathy-Type T-cell Lymphoma. British J Haematology 2008 May; 142: 480–501
Mora O, Zucca E. Management of elderly patients with hematological neoplasms. Ann Oncol 2007 Jan;18 Suppl 1: 49-53.
Ghielmini M, Mora O. Does the FLIPI apply to grade 3 follicular lymphoma? Blood. 2005 Jun 15;105(12):4892.
Riccardi A, Mora O, Tinelli C, Porta C, Danova M, Brugnatelli S, Grasso D, Tolcà B, Spanedda R, De Paoli A, Barbarano L, Cavanna L, Giordano M, Delfini C, Nicoletti G, Bergonzi C, Rinaldi E, Piccinini L, Ascari E. Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol. Eur J Cancer. 2003 Jan;39(1):31-7.
Sessa C, Weigang-Köhler K, Pagani O, Greim G, Mora O, De Pas T, Burgess M, Weimer I, Johnson R. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. Eur J Cancer. 2002 Dec;38(18):2388-96.
de Jonge MJ, Verweij J, van der Gaast A, Valota O, Mora O, Planting AS, Mantel MA, Bosch SV, Lechuga MJ, Fiorentini F, Hess D, Sessa C. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline administered intravenously to patients with advanced solid tumours. Eur J Cancer. 2002 Dec;38(18):2407-15.
Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Giordano M, Delfini C, Nicoletti G, Bergonzi C, Rinaldi E, Piccinini L, Ascari E. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer. 2000 Apr;82(7):1254-60.
Riccardi A, Valentini D, Mora O. I difosfonati in Oncologia. Arg Oncol, 1998; 19: 111-119.
Danova M, Perotti C, Mora O, Lucotti C, Torretta L, Comolli G, Riccardi A, Salvaneschi L, Ascari E. Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary breast cancer. Oncol Rep. 1998 Mar-Apr;5(2):427-9.
Riccardi A, Mora O, Brugnatelli S, Tinelli C, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Bergonzi C, Giordano M, Delfini C, Nicoletti G, Rinaldi E, Piccinini L, Valentini D, Ascari E. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer. 1998;77(3):485-91.
Brugnatelli S, Riccardi A, Ucci G, Mora O, Barbarano L, Piva N, Piccinini L, Bergonzi C, De Paoli A, Di Stasi M, Rinaldi E, Trotti G, Petrini M, Ascari E. Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer. 1996 Mar;73(6):794-7.
Danova M, Rosti V, Mora O, Perotti C, Cazzola M, Riccardi A, Ascari E. The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer. Oncol Rep. 1995 Nov;2(6):1075-8.
Riccardi A, Mora O, Danova M, Tinelli C. Fattori di crescita mielopoietici: rapporto costo-efficacia: G-CSF e GM-CSF nel trattamento della neutropenia postchemioterapia. Arg Oncol, 1995; 16: 363-372.
Danova M, De Renzis MR, Girino M, Valenti L, Mora O, Scabini M, Mazzini G, Riccardi A. DNA content and cell kinetics in colorectal carcinoma: flow cytometric analysis of primary tumor and liver metastases. Tumori. 1995 May-Jun;81(3 Suppl):12-5.
Riccardi A, Giordano M, Brugnatelli S, Ucci G, Danova M, Mora O, Fava S, Ascari E. Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: a randomised study in advanced breast cancer. Eur J Cancer. 1995;31A(9):1549-51.
Riccardi A, Brugnatelli S, Giordano M, Mora O. Fattori di prognosi nel carcinoma mammario invasivo con linfonodi ascellari istologicamente negativi. Arg Oncol, 1994; 15: 361-366
Riccardi A, Ucci G, Luoni R, Brugnatelli S, Mora O, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Alberio F, et al. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer. 1994 Dec;70(6):1203-10.
Riccardi A, Ucci G, Brugnatelli S, Mora O, Merlini G, Piva N, Depaoli A, Barbarano L, Distasi M, Alberio F, Nicoletti G, Morandi S, Rinaldi E, Piccinini L, Ascari E. A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma. Int J Oncol. 1994 Oct;5(4):833-9.